"The Food and Drug Administration (FDA) has announced that, in response to a trend in which caffeine is being added to a growing number of products, the agency will investigate the safety of caffeine in food products, particularly its effects on c"...
IN THE EVENT OF FAT OVERLOAD DURING THERAPY, STOP THE INFUSION OF INTRALIPID® 20% UNTIL VISUAL INSPECTION OF THE PLASMA, DETERMINATION OF TRIGLYCERIDE CONCENTRATIONS, OR MEASUREMENT OF PLASMA LIGHT-SCATTERING ACTIVITY BY NEPHELOMETRY INDICATES THE LIPID HAS CLEARED. RE-EVALUATE THE PATIENT AND INSTITUTE APPROPRIATE CORRECTIVE MEASURES. SEE WARNINGS AND PRECAUTIONS.
THE ADMINISTRATION OF INTRALIPID® 20% (20% i.v. fat emulsion) IS CONTRAINDICATED IN PATIENTS WITH DISTURBANCES OF NORMAL FAT METABOLISM SUCH AS PATHOLOGIC HYPERLIPEMIA, LIPOID NEPHROSIS OR ACUTE PANCREATITIS IF ACCOMPANIED BY HYPERLIPIDEMIA.
Last reviewed on RxList: 7/30/2007
This monograph has been modified to include the generic and brand name in many instances.
Additional Intralipid 20% Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Weight Loss Wisdom
Get tips, recipes and inspiration.